NCT07121413RecruitingPhase 2
A Phase IIa, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
Shanghai Synvida Biotechnology Co.,Ltd.12 sites in 1 country48 target enrollmentStarted: November 4, 2025Last updated:
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Sponsor
- Enrollment
- 48
- Locations
- 12
- Primary Endpoint
- Incidence of Treatment-Emergent Adverse Events
Study Overview
Brief Summary
The purpose of this study is to evaluate the safety, tolerability, PK and immunogenicity of SV001 in patients with idiopathic pulmonary fibrosis.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 40 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Subjects with a confirmed diagnosis of IPF and pulmonary function meeting the protocol-specified criteria;
- •Subjects must agree to use highly effective contraception during the study and for 6 months after the last administration of the study drug;
- •Subjucts must be able to understand the study, voluntarily provide written informed consent, and be willing and able to comply with all study-related procedures.
Exclusion Criteria
- •Subjects with a history of drug or other allergies, or those judged by the investigator to be potentially allergic to the study drugs;
- •Presence of any other clinically significant pulmonary diseases besides IPF at screening;
- •Any known contraindications to performing pulmonary function tests at screening;
- •Respiratory or systemic infections requiring anti-infective therapy within 1 month prior to randomization;
- •Acute exacerbation of IPF within 4 months prior to randomization;
- •Use of any medication known to cause or worsen pulmonary fibrosis, as assessed by the investigator, within 3 months prior to screening;
- •History of smoking within 3 months prior to screening, or unwillingness to quit smoking throughout the study period;
- •Presence of clinically significant cardiovascular, cerebrovascular, hematological, neurological, psychiatric, or metabolic disease at screening, or plans for major surgery during the study period;
- •Presence of specified abnormal laboratory test results at screening;
- •Evidence of renal impairment or end-stage renal disease requiring dialysis at screening;
- •Active hepatitis virus infection; history of acquired or congenital immunodeficiency disease;
- •History of malignancy within 5 years prior to screening;
- •Difficulty with venipuncture or a history of needle phobia or blood phobia;
- •Positive pregnancy tests or currently lactating at screening;
- •Participation in another clinical trial and receipt of other investigational drugs within 3 months prior to randomization;
- •Any other condition that the investigator consider unsuitable for participation in the study.
Arms & Interventions
SV001
Experimental
Intervention: SV001 (Drug)
Placebo
Placebo Comparator
Intervention: Placebo (Drug)
Outcomes
Primary Outcomes
Incidence of Treatment-Emergent Adverse Events
Time Frame: Approximately 1 years
Adverse event type, incidence, duration
Secondary Outcomes
- Peak Plasma Concentration (Cmax)(Approximately 1 years)
- Peak time（Tmax）(Approximately 1 years)
- Area under the plasma concentration versus time curve (AUC)(Approximately 1 years)
- half-life（T1/2）(Approximately 1 years)
- Immunogenicity(Approximately 1 years)
Investigators
Study Sites (12)
Loading locations...
Similar Trials
Recruiting
Phase 1
A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers.Idiopathic Pulmonary FibrosisNCT06267183Shanghai Synvida Biotechnology Co.,Ltd.53
Unknown
Phase 1
The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With Inactivated COVID-19 Vaccine.COVID-19SARS-CoV-2 InfectionNCT05043285Sinocelltech Ltd.300
Unknown
Phase 1
The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With mRNA COVID-19 Vaccine.COVID-19SARS-CoV-2 InfectionNCT05043311Sinocelltech Ltd.300
Unknown
Phase 2
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E in Population Aged ≥18 Years Previously Fully Vaccinated With mRNA COVID-19 VaccineCOVID-19Sars-CoV-2 InfectionNCT05238441Sinocelltech Ltd.360
Withdrawn
Phase 2
A Study to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E (Two Recombinant Protein COVID-19 Vaccines) in Population Aged ≥12 YearsCOVID-19SARS-CoV-2 InfectionNCT05308602Sinocelltech Ltd.